- Home
- CCBG vs ABUS Comparison
CCBG vs ABUS Comparison
Compare CCBG & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCBG | ABUS |
|---|---|---|
| Founded | 1895 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.1M | 839.5M |
| IPO Year | 1994 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CCBG | ABUS |
|---|---|---|
| Price | $51.12 | $5.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $50.00 | $5.00 |
| AVG Volume (30 Days) | 50.3K | ★ 4.0M |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | 15.38 | ★ 55.26 |
| EPS | ★ 0.92 | 0.84 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.17 | $239.71 |
| P/E Ratio | $55.41 | ★ $6.07 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $38.27 | $3.50 |
| 52 Week High | $53.60 | $5.45 |
Technical Indicators
Market Signals| Indicator | CCBG | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 62.35 |
| Support Level | $50.98 | $4.16 |
| Resistance Level | $51.04 | $5.42 |
| Average True Range (ATR) | 0.93 | 0.16 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 37.57 | 63.33 |
Price Performance
Historical ComparisonAbout CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.